Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals announced strong second quarter 2026 financial results, exceeding expectations with record total revenues of $1.2 billion and raising its full-year revenue guidance.

Jazz Pharmaceuticals plc shareholders approved director elections, auditor ratification, executive compensation, and share issuance authorities at the 2026 Annual General Meeting.

Jazz Pharmaceuticals announced first quarter 2026 financial results, with total revenues reaching $1.1 billion, a 19% year-over-year increase, driven by strong commercial execution across its franchises.

Jazz Pharmaceuticals announced record 2025 total revenues of $4.3 billion, driven by key product growth and provided optimistic 2026 financial guidance.

Jazz Pharmaceuticals expects to meet its 2025 total revenue guidance and highlights strong performance across its rare disease portfolio, including key product sales and pipeline advancements.

Jazz Pharmaceuticals announced positive top-line results from its Phase 3 HERIZON-GEA-01 trial for Ziihera in HER2-positive gastroesophageal adenocarcinoma.

Jazz Pharmaceuticals plc announced its second quarter 2026 financial results, showcasing significant revenue increases driven by its key sleep and epilepsy medications, alongside progress in its oncology pipeline.

Jazz Pharmaceuticals reports strong Q1 2026 results with significant revenue growth driven by Xywav and oncology products, alongside a substantial gain from a PRV sale.

Jazz Pharmaceuticals reported a 7% increase in total revenues for Q3 2025, driven by strong performance from Xywav and Epidiolex, alongside new product approvals, despite ongoing litigation costs and competitive pressures.

Jazz Pharmaceuticals reported a significant net loss in Q2 2025, primarily driven by a large in-process R&D expense from the Chimerix acquisition and Xyrem antitrust litigation settlements, despite modest revenue growth.

Jazz Pharmaceuticals updates its executive severance benefit plan and files its Q1 2025 report, revealing key financial metrics and strategic developments.

Jazz Pharmaceuticals' Q3 2024 results show revenue growth driven by Xywav and strategic investments in research and development.

Jazz Pharmaceuticals filed an amendment to its 2025 Annual Report on Form 10-K to include required proxy statement information and updated certifications.

Jazz Pharmaceuticals plc reports a 5% increase in total revenues for 2025, driven by strong growth in rare oncology and epilepsy products, despite declines in oxybate sales due to generic competition.

Jazz Pharmaceuticals files an amendment to its 2024 Annual Report on Form 10-K to include information previously intended to be incorporated by reference from its proxy statement.

Jazz Pharmaceuticals' 2024 10-K filing reveals a focus on revenue diversification, oncology and neuroscience pipeline advancement, and commitment to a high-performance culture.

Jazz Pharmaceuticals plc has filed an amendment to its annual report, providing detailed information on executive compensation, corporate governance, and financial performance for the fiscal year ended December 31, 2023.

Jazz Pharmaceuticals provides a detailed overview of its share capital structure, including authorized and issued shares, dividend policies, and repurchase options in a recent SEC filing.

Jazz Pharmaceuticals Director Bruce C. Cozadd sold 6,000 ordinary shares on July 1, 2026, under a pre-arranged 10b5-1 trading plan.

Jazz Pharmaceuticals executive Samantha Pearce reported a disposition of ordinary shares, primarily to cover tax obligations.

Renee D. Gala, President & CEO of Jazz Pharmaceuticals, reported a transaction involving the sale of ordinary shares.

Jazz Pharmaceuticals plc reports a transaction where EVP Robert Iannone sold shares to cover tax obligations.

Jazz Pharmaceuticals plc reports a transaction where EVP & Chief Legal Officer Neena M. Patil disposed of shares to cover tax obligations.

Jazz Pharmaceuticals plc executive Philip L. Johnson reported a transaction involving the withholding of shares to cover tax obligations and an acquisition of shares through an employee stock purchase plan.

Jazz Pharmaceuticals plc announced its 2026 Annual General Meeting of Shareholders will be held on July 23, 2026, to vote on director elections, auditor ratification, executive compensation, and share issuance authorities.

Jazz Pharmaceuticals plc is reminding its employee-shareholders to cast their votes for the upcoming Annual General Meeting on July 24, 2025, with board and management recommending a 'FOR' vote on all proposals.

Jazz Pharmaceuticals plc announced the appointment of Renee Gala as its new President and Chief Executive Officer, effective August 11, 2025, alongside significant adjustments to her compensation and an increase in the Board of Directors' size.

Jazz Pharmaceuticals Public Limited Company has filed a Definitive Proxy Statement (DEFA14A) with the SEC, outlining information for an upcoming shareholder meeting.

Jazz Pharmaceuticals plc has announced its 2025 Annual General Meeting to be held on July 24, 2025, seeking shareholder approval for the election of four directors, ratification of KPMG as auditors, advisory approval of executive compensation, and renewal of authority to allot shares for cash without pre-emption rights.

Jazz Pharmaceuticals encourages its employee shareholders to vote on key proposals at the upcoming Annual General Meeting (AGM) on July 25, 2024.

Vanguard Capital Management has reported beneficial ownership of over 3.1 million shares, representing 5.04% of Jazz Pharmaceuticals PLC's common stock.

The Vanguard Group reports zero beneficial ownership in Jazz Pharmaceuticals PLC following an internal realignment.